BR112018000660A2 - peptídeos anti-inflamatórios e seu uso - Google Patents

peptídeos anti-inflamatórios e seu uso

Info

Publication number
BR112018000660A2
BR112018000660A2 BR112018000660-2A BR112018000660A BR112018000660A2 BR 112018000660 A2 BR112018000660 A2 BR 112018000660A2 BR 112018000660 A BR112018000660 A BR 112018000660A BR 112018000660 A2 BR112018000660 A2 BR 112018000660A2
Authority
BR
Brazil
Prior art keywords
antiinflammatory
region
fragment
amino acid
methionine
Prior art date
Application number
BR112018000660-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Khaldi Nora
Lopez Cyril
Adlefio Alessandro
Original Assignee
Nuritas Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15177017.9A external-priority patent/EP3118216A1/en
Priority claimed from EP15177013.8A external-priority patent/EP3118215A1/en
Application filed by Nuritas Limited filed Critical Nuritas Limited
Publication of BR112018000660A2 publication Critical patent/BR112018000660A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/02Preparations for cleaning the hair
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
BR112018000660-2A 2015-07-16 2016-07-18 peptídeos anti-inflamatórios e seu uso BR112018000660A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15177013.8 2015-07-16
EP15177017.9A EP3118216A1 (en) 2015-07-16 2015-07-16 Cellular growth and proliferation promoting peptides, and uses thereof
EP15177013.8A EP3118215A1 (en) 2015-07-16 2015-07-16 Anti-inflammatory peptides, and uses thereof
EP15177017.9 2015-07-16
PCT/EP2016/067090 WO2017009484A1 (en) 2015-07-16 2016-07-18 Anti-inflammatory peptides, and uses thereof

Publications (1)

Publication Number Publication Date
BR112018000660A2 true BR112018000660A2 (pt) 2019-05-14

Family

ID=56686757

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018000660-2A BR112018000660A2 (pt) 2015-07-16 2016-07-18 peptídeos anti-inflamatórios e seu uso

Country Status (12)

Country Link
US (4) US10463591B2 (enExample)
EP (3) EP3747425A1 (enExample)
JP (3) JP2018523703A (enExample)
KR (3) KR102576571B1 (enExample)
CN (2) CN108348568B (enExample)
AU (2) AU2016293129B2 (enExample)
BR (1) BR112018000660A2 (enExample)
CA (1) CA2992378A1 (enExample)
DK (1) DK3322430T3 (enExample)
ES (1) ES2806989T3 (enExample)
MX (2) MX377692B (enExample)
WO (1) WO2017009484A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2932498T3 (es) * 2016-12-05 2023-01-20 Nuritas Ltd Composiciones que comprenden el péptido WKDEAGKPLVK
JP7340314B2 (ja) * 2020-01-15 2023-09-07 Tdk株式会社 米に含まれるタンパク質の含有量を測定する方法
KR102354916B1 (ko) * 2020-02-11 2022-01-26 주식회사 쓰리빅스 신규 펩타이드 3ps_i014 및 이의 용도
FR3114744B1 (fr) 2020-10-02 2024-01-05 Basf Beauty Care Solutions France Sas Nouvelle utilisation d’un peptide pour améliorer le confort de la peau et/ou des muqueuses et/ou l’apparence des phanères
US20240043474A1 (en) * 2020-12-16 2024-02-08 Ajou University Industry-Academic Cooperation Foundation Anti-inflammatory peptide for preventing or treating atopic dermatitis
CN114478702B (zh) * 2022-04-06 2023-12-12 中南林业科技大学 一种米糠来源短肽及其在治疗皮肤损伤中的应用
CN116253782B (zh) * 2022-09-08 2024-06-04 浙江大学 一种广谱抗菌肽ktr及其应用
CN116375828B (zh) * 2022-09-08 2024-06-04 浙江大学 一种具有抗菌活性的抗菌肽kta及其应用
FR3141066A1 (fr) * 2022-10-24 2024-04-26 Basf Beauty Care Solutions France Sas Nouvelle utilisation d’un peptide pour améliorer la matrice extracellulaire du derme de la peau et/ou des muqueuses
CN116491631B (zh) * 2023-05-26 2024-06-25 青岛农业大学 一种预制菜红烧肉及其制备方法
WO2024259556A1 (en) * 2023-06-19 2024-12-26 Viage Therapeutics, Inc. Uses of therapeutic peptides
CN118812660A (zh) * 2023-06-29 2024-10-22 长沙理工大学 一种米渣蛋白源免疫抑制肽及其应用
WO2025133189A1 (en) * 2023-12-20 2025-06-26 Nuritas Limited Sleep promoting peptides and the use thereof
CN117986337B (zh) * 2024-02-02 2024-08-16 杭州御寿生物科技有限公司 一种提高免疫力的益生菌组合物以及在治疗疾病中的应用
CN120590476A (zh) * 2025-08-06 2025-09-05 浙江诺衍生物科技有限公司 一种有助于降血糖的七肽及其应用
CN120574921A (zh) * 2025-08-06 2025-09-02 浙江诺衍生物科技有限公司 一种有助于降血糖的大米肽及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5520935A (en) 1991-03-07 1996-05-28 Novo Nordisk A/S Method for production of pea protein hydrolyzate
US5516642A (en) 1992-11-16 1996-05-14 Bristol-Myers Squibb Company Polypeptides derived from major histocompatibility complex Class I antigen
JP2673659B2 (ja) 1994-02-11 1997-11-05 株式会社ホーネンコーポレーション ペプチド
US5688489A (en) * 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
IT1313572B1 (it) 1999-07-27 2002-09-09 Enichem Spa Procedimento per la preparazione di epossidi.
US20110131679A2 (en) * 2000-04-19 2011-06-02 Thomas La Rosa Rice Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
JP2001335596A (ja) 2000-05-24 2001-12-04 Kenji Sakamoto 新規ペプチド及びその医薬用途
AR035860A1 (es) 2001-04-17 2004-07-21 Femtolink Biotechnologies Llc Metodos de deteccion por espectrometria de masa y cuantificacion de proteinas blanco especificas en muestras biologicas complejas
WO2004042026A2 (en) 2002-11-04 2004-05-21 Florida State University Research Foundation NUCLEIC ACID AND ALLERGENIC POLYPEPTIDES ENCODED THEREBY IN CASHEW NUTS (Anacardium occidentale)
SE0300795D0 (sv) 2003-03-24 2003-03-24 Isconova Ab Composition comprising iscom particles and live micro-organisms
TW200509961A (en) 2003-05-23 2005-03-16 Pestka Biomedical Lab Inc Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections
CN1893911B (zh) 2003-11-17 2010-12-29 赛德玛公司 含有四肽和三肽混合物的配方
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
WO2007000770A2 (en) 2005-06-29 2007-01-04 Hadasit Medical Research Services & Development Ltd. Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes
US8105572B2 (en) 2007-05-18 2012-01-31 New York University Method of treating tuberculosis with interferons
KR100759495B1 (ko) 2006-02-17 2007-09-18 재단법인서울대학교산학협력재단 친수성 생리활성 펩타이드와 소수성 물질을 포함한자기조립 나노구조체
EP2039366A4 (en) 2006-04-21 2010-01-06 Meiji Seika Kaisha COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT
US9034402B2 (en) * 2007-04-16 2015-05-19 Solae, Llc Protein hydrolysate compositions having improved sensory characteristics and physical properties
EP3567113A1 (en) 2007-06-06 2019-11-13 Monsanto Technology LLC Genes and uses for plant enhancement
NZ583429A (en) * 2007-08-24 2012-08-31 Mylexa Pty Ltd Peptides and proteins capable of inhibiting and/or preventing mast cell activation
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
CN102665749B (zh) * 2009-07-13 2014-09-17 不二制油株式会社 口服抗炎剂和口服抗炎肽
WO2011122937A1 (en) 2010-03-29 2011-10-06 N.V. Nutricia Pea protein peptides with anti helicobacter pylori activity
ES2397890B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel y/o mucosas y su uso en composiciones cosméticas o farmacéuticas.
WO2013092851A1 (en) * 2011-12-21 2013-06-27 Laboratorios Ordesa, S.L. Process for obtaining rice protein hydrolysates useful in the prevention and/or treatment of obesity
HK1212237A1 (en) 2012-08-31 2016-06-10 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
JP2016508510A (ja) * 2013-02-19 2016-03-22 ダノン,エセ.アー. 肥満障害に対する機能性ペプチド
WO2016090252A1 (en) 2014-12-04 2016-06-09 Mary Kay Inc. Topical skin care composition comprising trifluoroacetyl tripeptide-2
US20170183386A1 (en) 2015-07-16 2017-06-29 Nuritas Limited Peptides, and uses thereof

Also Published As

Publication number Publication date
EP3322430A1 (en) 2018-05-23
EP3954700A1 (en) 2022-02-16
MX2020010806A (es) 2020-10-28
US20190029939A1 (en) 2019-01-31
KR102576571B1 (ko) 2023-09-11
EP3747425A1 (en) 2020-12-09
CN108348568B (zh) 2021-12-28
JP7288026B2 (ja) 2023-06-06
US20200060956A1 (en) 2020-02-27
AU2021202423A1 (en) 2021-05-13
US20220233425A1 (en) 2022-07-28
CN108348568A (zh) 2018-07-31
EP3322430B1 (en) 2020-03-25
DK3322430T3 (da) 2020-06-29
KR102307260B1 (ko) 2021-10-01
US11779531B2 (en) 2023-10-10
WO2017009484A1 (en) 2017-01-19
AU2016293129A1 (en) 2018-02-01
KR20210120134A (ko) 2021-10-06
MX2018000697A (es) 2018-08-15
US20240238184A1 (en) 2024-07-18
US11253456B2 (en) 2022-02-22
CN114835784A (zh) 2022-08-02
JP2018523703A (ja) 2018-08-23
KR20230132623A (ko) 2023-09-15
MX377692B (es) 2025-03-10
JP7739355B2 (ja) 2025-09-16
CN114835784B (zh) 2025-06-13
JP2023109950A (ja) 2023-08-08
AU2016293129B2 (en) 2021-01-28
ES2806989T3 (es) 2021-02-19
JP2022009415A (ja) 2022-01-14
US10463591B2 (en) 2019-11-05
KR20180029237A (ko) 2018-03-20
CA2992378A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
PE20181923A1 (es) Neoantigenos y metodos de su uso
CO6190536A2 (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
NZ596787A (en) Growth hormone polypeptides and methods of making and using same
EA201491049A1 (ru) Противораковый слитый белок
PE20130041A1 (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)
BR112013013548B8 (pt) Proteína de fusão anticancerígena
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
BR112016015512A2 (pt) proteínas quiméricas de fator viii e suas utilizações
EA201100038A1 (ru) Коагонисты глюкагонового рецептора/glp-1-рецептора
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
DE60030450D1 (de) Von MUC-1 abgeleitete Peptide
EA201491277A1 (ru) Противораковый слитый белок
BR112022010153A2 (pt) Peptídeos, ácido nucleico, polipeptídeo, composição, complexo bioluminescente, métodos, dipeptídeo, sistema e kit
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
FI3737399T3 (fi) ATF5-peptidivariantit ja niiden käytöt
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements